Search results for "reuma"

showing 10 items of 152 documents

Metacarpophalangeal joint of the thumb arthrodesis using intramedullary interlocking screws XMCP™

2018

Abstract The study objective was to assess the results of a thumb metacarpophalangeal joint (MCPJ) arthrodesis using intramedullary interlocking screws at 25°, XMCP ™ (Extremity Medical, Parsippany, NJ). Radiographs evaluated the angle of arthrodesis, time of fusion and fixation of the implant. Clinical and functional outcomes were assessed using the DASH questionnaire and the VAS scale. Any complications found during surgery or the follow-up period were noted. We studied 9 patients. The mean follow-up was 27.6 months. Patients showed clinical and radiological evidence of fusion in an average of 8 weeks, the angle of fusion was 25°. There were no complications and no implant had to be remov…

MaleArthrodesismedicine.medical_treatmentRadiographyBone ScrewsArthrodesisThumblaw.inventionArthritis RheumatoidMetacarpophalangeal JointIntramedullary rod03 medical and health sciencesFixation (surgical)0302 clinical medicinelawmedicineHumansOrthopedics and Sports Medicine030212 general & internal medicineAgedOrthodontics030222 orthopedicsbusiness.industryArthrodesis Arthrosis Articulación metacarpofalángica Artritis reumatoide Artrodesis Artrosis Metacarpophalangeal joint Rheumatoid arthritisMetacarpophalangeal jointMiddle AgedTreatment Outcomemedicine.anatomical_structureThumbRadiological weaponFemaleSurgeryImplantJoint DiseasesbusinessFollow-Up StudiesRevista Española de Cirugía Ortopédica y Traumatología (English Edition)
researchProduct

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study

2019

Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease…

MaleCrohn’s diseaseSettore MED/16 - REUMATOLOGIAPsoriaticCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Hepatology; GastroenterologyInflammatory bowel disease0302 clinical medicineClinical endpointCrohn's disease Psoriasis Psoriatic arthritis Ulcerative colitis UstekinumabCrohn's diseaseSettore MED/12 - GastroenterologiaGastroenterologyMiddle AgedUlcerative colitisCrohn's diseaseTreatment OutcomeItaly030220 oncology & carcinogenesisPsoriatic arthritis030211 gastroenterology & hepatologyFemaleUstekinumabmedicine.drugAdultmedicine.medical_specialty03 medical and health sciencesPsoriatic arthritisCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Adult; Aged; Arthritis Psoriatic; Dermatologic Agents; Female; Humans; Inflammatory Bowel Diseases; Italy; Logistic Models; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young AdultYoung AdultInternal medicinePsoriasisUstekinumabmedicineHumansPsoriasisAgedRetrospective StudiesHepatologybusiness.industryArthritisArthritis Psoriaticmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesCrohn’s disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; UstekinumabLogistic ModelsUlcerative colitisConcomitantDermatologic Agentsbusiness
researchProduct

Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease

1996

Our investigation aimed at verifying diastolic abnormalities in rheumatoid patients, without clinically evident cardiovascular disease and other confounding complaints, by using pulsed Doppler examination of transmitral blood flow. We selected 40 patients fulfilling revised American Rheumatism Association (ARA) criteria for the diagnosis of rheumatoid arthritis having no symptoms of cardiac disease or clinical findings of other extracardiac diseases. We also studied 40 rheumatoid-matched healthy volunteers as a control group. An echocardiographic examination was carried out on each subject. Left ventricular structural and functional measurements were obtained. Interventricular, septal thick…

MaleDuplex ultrasonographymedicine.medical_specialtySettore MED/09 - Medicina InternaHeart diseaseClinical BiochemistryDiastoleHemodynamicsBlood PressureDoppler echocardiographyBiochemistryAsymptomaticVentricular Function LeftBody Mass IndexArthritis RheumatoidVentricular Dysfunction LeftHeart RateInternal medicineMedicineHumansskin and connective tissue diseasesmedicine.diagnostic_testbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheEchocardiography DopplerSurgerySettore MED/16 - Reumatologiamedicine.anatomical_structureVentricleCardiovascular DiseasesRheumatoid arthritiscardiovascular systemCardiologyRegression AnalysisFemalemedicine.symptombusinessDoppler echocardiography left ventricular filling rheumatoid arthritis
researchProduct

Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis

2015

OBJECTIVE: GCA is a large- and medium-vessel arteritis characterized by a range of histological patterns of vascular wall injury. The aim of this study was to immunologically characterize the various histological patterns of GCA. METHODS: Thirty-five consecutive patients with biopsy-proven GCA and 15 normal controls were studied. IL-8, IL-9, IL-9R, IL-17, IL-4, TGF-β and thymic stromal lymphopoietin expression was evaluated by RT-PCR and immunohistochemistry on artery biopsy specimens. Confocal microscopy was used to characterize the phenotypes of IL-9-producing and IL-9R-expressing cells. Five additional patients who had received prednisone when the temporal artery biopsy was performed wer…

MalePathologyBiopsyT-LymphocytesSettore BIO/13 - Biologia ApplicataTransforming Growth Factor betaTh9Pharmacology (medical)Aged 80 and overMicroscopy Confocalmedicine.diagnostic_testSmall vessel vasculitisVasa vasorum vasculitiInterleukin-17vasa vasorum vasculitis Giant cell arteritiMiddle AgedTemporal Arteriesmedicine.anatomical_structurePhenotypeVasa vasorum vasculitisSmall vessel vasculitiCytokinesFemaleTh17medicine.symptomVasculitisgiant cell arteritimedicine.medical_specialtyThymic stromal lymphopoietinGiant Cell ArteritisInflammationThymic Stromal LymphopoietinRheumatologyBiopsyTh17; Th9; giant cell arteritis; small vessel vasculitis; vasa vasorum vasculitismedicineHumansInterleukin 9ArteritisGlucocorticoidsAgedbusiness.industryInterleukin-9Vascular System Injuriesmedicine.diseaseGiant cell arteritisSettore MED/16 - ReumatologiaVasa vasorumCase-Control StudiesImmunologyPrednisonebusinessBiomarkers
researchProduct

ASSOCIATION OF RENAL RESISTIVE INDEX WITH MARKERS OF EXTRARENAL VASCULAR CHANGES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

2016

Introduction: Recent data suggest that renal hemodynamic parameters obtained by duplex Doppler sonography, especially the intrarenal resistive index (RRI), may be associated with systemic vascular changes. However, limited and conflicting data exist about the relationship between aortic stiffness and RI in autoimmune diseases, like systemic lupus erythematosus (SLE). Aim: To evaluate the relationship between RRI and arterial stiffness, assessed by aortic pulse wave velocity (aPWV), and between RRI and carotid atherosclerosis, evaluated by intima-media thickness (IMT) measurement in patients with SLE. Methods: In this cross-sectional study, we enrolled 39 SLE subjects (mean age 39 years) tha…

MalePathologyRadiology Nuclear Medicine and ImagingSettore MED/09 - Medicina InternaAcoustics and UltrasonicsSLE030204 cardiovascular system & hematologyCarotid Intima-Media Thickness0302 clinical medicineLupus Erythematosus Systemicskin and connective tissue diseasesPulse wave velocityAortaRadiological and Ultrasound TechnologyRENAL RESISTIVE INDEXAortic stiffneAtherosclerosicardiovascular systemCardiologyAortic stiffnessFemaleAdultmedicine.medical_specialtyMean arterial pressureAmbulatory blood pressureBiophysicsRenal functionSystemic lupus erythematosuPulse Wave AnalysisSensitivity and SpecificityRenal Circulation03 medical and health sciencesCAROTID IMTVascular StiffnessInternal medicinemedicineHumansIn patient030203 arthritis & rheumatologySettore MED/14 - NefrologiaRenal hemodynamicbusiness.industryReproducibility of ResultsUltrasonography Dopplermedicine.diseaseAtherosclerosisResistive indexPulse wave velocitySettore MED/16 - ReumatologiaArterial stiffnessbusinesshuman activitiesBiomarkers
researchProduct

Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients

2021

Abstract Objective To establish optimal cut-off values for the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromialgia Assessment Scale (FAS 2019mod), and the Polysymptomatic Distress Scale (PDS) in order to distinguish five levels of FM disease severity. Methods Consecutive FM patients were evaluated with the three clinimetric indices, and each patient was required to answer the anchor question: ‘In general, would you say your health is 1 = very good, 2 = good, 3 = fair, 4 = poor, or 5 = very poor?’—which represented the external criterion. Cut-off points were established through the interquartile reconciliation approach. Results The study sample consisted…

MalePercentileSettore MED/16 - REUMATOLOGIAFibromyalgiaCross-sectional studyseverityDiseaseSeverity of Illness IndexEconomica0302 clinical medicinemodifiedInterquartile rangeRetrospective StudieFibromyalgiaSurveys and QuestionnairesSurveys and QuestionnairePharmacology (medical)030212 general & internal medicinecut-off pointsPain MeasurementFibromyalgia Assessment Status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severity; Cross-Sectional Studies; Female; Fibromyalgia; Follow-Up Studies; Humans; Incidence; Italy; Male; Middle Aged; Pain Measurement; Prognosis; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of LifeIncidencerevised Fibromyalgia Impact Questionnairecut-off points; fibromyalgia; Fibromyalgia Assessment Status; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severityMiddle AgedPrognosisDistressItalyFemalefibromyalgiaFibromyalgia Assessment StatusHumanmedicine.medical_specialtyPrognosiRevised Fibromyalgia Impact QuestionnaireFollow-Up Studie03 medical and health sciencesRheumatologyInternal medicineSeverity of illnesscut-off pointmedicineHumansRetrospective Studies030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industrymedicine.diseaseFibromyalgia Assessment StatuCross-Sectional StudiesFibromyalgia; severity; cut-off points; revised Fibromyalgia Impact Questionnaire; modified; Fibromyalgia Assessment Status; polysymptomatic distress scalepolysymptomatic distress scalefibromyalgia assessment status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised fibromyalgia impact questionnaire; severityQuality of LifebusinessFollow-Up Studies
researchProduct

Interleukin-36α axis is modulated in patients with primary Sjögren's syndrome.

2015

Summary The aim of this study was to investigate the expression of the interleukin (IL)-36 axis in patients with primary Sjögren's syndrome (pSS). Blood and minor labial salivary glands (MSG) biopsies were obtained from 35 pSS and 20 non-Sjögren's syndrome patients (nSS) patients. Serum IL-36α was assayed by enzyme-linked immunosorbent assay (ELISA). IL-36α, IL-36R, IL-36RA, IL-38, IL-22, IL-17, IL-23p19 and expression in MSGs was assessed by reverse transcription–polymerase chain reaction (RT–PCR), and tissue IL-36α and IL-38 expression was also investigated by immunohistochemistry (IHC). αβ and γδ T cells and CD68+ cells isolated from MSGs were also studied by flow cytometry and confocal …

MaleReceptors Antigen T-Cell alpha-betaT-LymphocytesSalivary GlandsIL-36aIL-36a IL-38 IL36RA Sjogren's syndrome γδT cellsImmunology and AllergyMedicinemedicine.diagnostic_testSalivary glandbiologyCD68γδT cellsInterleukin-17TranslationalIL-36a; IL-38; IL36RA; Sjögren's syndrome; γδ T cellsInterleukinReceptors Antigen T-Cell gamma-deltaMiddle Agedmedicine.anatomical_structureSjogren's SyndromeImmunohistochemistryFemaleSjögren's syndromeInterleukin 17Signal TransductionAdultmedicine.medical_specialtyCD3ImmunologyPrimary Cell CultureAntigens Differentiation Myelomonocyticγδ T cellsIL36RAFlow cytometrystomatognathic systemAntigens CDInternal medicineHumansbusiness.industryInterleukinsReceptors InterleukinIL-38stomatognathic diseasesSettore MED/16 - ReumatologiaEndocrinologyGene Expression RegulationCell cultureCase-Control StudiesImmunologybiology.proteinInterleukin-23 Subunit p19businessInterleukin-1
researchProduct

Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.

2015

Summary The aim of this study was to elucidate more clearly the role of interleukin (IL)-18 in modulating the IL-22 pathway in primary Sjögren's syndrome (pSS) patients and in pSS-associated lymphomas. Minor salivary glands (MSGs) from patients with pSS and non-specific chronic sialoadenitis (nSCS), parotid glands biopsies from non-Hodgkin lymphomas (NHL) developed in pSS patients, were evaluated for IL-18, IL-22, IL-22 receptor 1 (IL-22R1), IL-22 binding protein (IL-22BP) and signal transducer and activator of transcription-3 (STAT-3) expression. MSGs IL-22R1-expressing cells were characterized by confocal microscopy and flow cytometry in pSS, nSCS and healthy controls. The effect of recom…

MaleSalivary Glandslaw.inventionInterleukin 22lawIL-22Immunology and AllergyMyeloid CellsIL-22R1Receptormedicine.diagnostic_testnon-Hodgkin lymphomaLymphoma Non-HodgkinInterleukin-17TranslationalInterleukin-18Lacrimal ApparatusInterleukinMiddle AgedHaematopoiesisSjogren's SyndromeIL-22BPRecombinant DNASjögren's syndromeInterleukin 18FemaleIL-18Signal TransductionAdultSTAT3 Transcription FactorImmunologyPrimary Cell CultureBiologyPeripheral blood mononuclear cellIL-18; IL-22; IL-22BP; IL-22R1; Sjögren's syndrome; non-Hodgkin lymphomaSialadenitisFlow cytometrystomatognathic systemmedicineHumansAgedInterleukinsMacrophagesReceptors InterleukinSettore MED/16 - Reumatologiastomatognathic diseasesGene Expression RegulationImmunologyLeukocytes MononuclearClinical and experimental immunology
researchProduct

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

2013

Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti–tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized …

MaleSettore MED/16 - REUMATOLOGIAArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidRheumatoidMonoclonalReceptorsMedicineOutpatient clinicLongitudinal StudiesRegistriesPrecision Medicineskin and connective tissue diseasesHumanizedRemission InductionAntibodies MonoclonalIndividualized MedicineMiddle AgedTreatment OutcomeRheumatoid arthritisAntirheumatic AgentsFemaleDrugmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAdalimumab; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Longitudinal Studies; Male; Middle Aged; Obesity; Precision Medicine; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaAntibodies Monoclonal HumanizedAntibodiesDose-Response RelationshipRheumatologyInternal medicineAdalimumabHumansObesityRisk factorAgedDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabRheumatologyInfliximabAged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Female; Humans; Immunoglobulin G; Individualized Medicine; Longitudinal Studies; Male; Middle Aged; Obesity; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaImmunoglobulin GImmunologybusinessTumor Necrosis FactorArthritis careresearch
researchProduct

Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.

2014

Objective.To evaluate the safety and efficacy of therapy with etanercept and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and mild hepatitis C virus (HCV) infection.Methods.In this prospective open study, 29 patients with active RA were randomly assigned to receive therapy with MTX alone, etanercept alone, or a combination of MTX and etanercept, and monitored up to 54 weeks. The primary endpoint was safety; secondary aims were efficacy as defined by the 44-joint Disease Activity Score (DAS44) and health assessment questionnaire (HAQ). Serum liver enzymes and HCV viral load were serially measured.Results.In the whole cohort, aspartate aminotransferase (AST) serum leve…

MaleSettore MED/16 - REUMATOLOGIATNF-α INHIBITORSHEALTH ASSESSMENT QUESTIONNAIREHepacivirusmedicine.disease_causeVirus ReplicationGastroenterologySeverity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidDISEASE ACTIVITY SCORELiver Function TestsRheumatoidReceptorsImmunology and AllergyProspective StudiesGISEAbiologyAlanine TransaminaseHepatitis CMiddle AgedViral LoadHepatitis CTreatment OutcomeRheumatoid arthritisAntirheumatic AgentsCombinationDrug Therapy CombinationFemaleTRANSAMINASESViral loadmedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtyHepatitis C virusImmunologyDrug TherapyRheumatologyInternal medicinemedicineHumansAspartate AminotransferasesAgedHepatitisbusiness.industryArthritisTNF-alpha INHIBITORS TRANSAMINASES GISEA DISEASE ACTIVITY SCORE HEALTH ASSESSMENT QUESTIONNAIREmedicine.diseaseRheumatologyMethotrexateAlanine transaminaseImmunoglobulin GImmunologybiology.proteinTumor Necrosis FactorbusinessThe Journal of rheumatology
researchProduct